BVS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
153.2M
+16.0%
132.1M
-16.3%
157.9M
+13.9%
138.7M
-6.1%
147.7M
Cost of Revenue
47.5M
+15.1%
41.3M
-15.9%
49.1M
+10.6%
44.4M
-2.5%
45.6M
Gross Profit
105.7M
+16.4%
90.8M
-16.6%
108.8M
+15.4%
94.2M
-7.7%
102.1M
Operating Expenses
86.5M
+5.1%
82.4M
-7.8%
89.3M
+7.6%
83.0M
-0.9%
83.7M
R&D
3.2M
+28.6%
2.5M
-18.0%
3.0M
+2.9%
2.9M
-7.8%
3.2M
SG&A
82.7M
+5.6%
78.3M
-5.4%
82.8M
+5.2%
78.7M
-0.6%
79.1M
Operating Income
19.1M
+127.3%
8.4M
-56.8%
19.5M
+73.2%
11.3M
-38.8%
18.4M
EBITDA
29.7M
+47.7%
20.1M
-39.9%
33.4M
+47.5%
22.7M
-25.5%
30.4M
Net Income
36.2M
+817.5%
3.9M
-77.2%
17.3M
+332.3%
4.0M
-56.8%
9.3M
EPS (Basic)
$0.49
+880.0%
$0.05
-77.3%
$0.22
+340.0%
$0.05
-54.5%
$0.11
EPS (Diluted)
$0.47
+1075.0%
$0.04
-80.0%
$0.20
+300.0%
$0.05
-54.5%
$0.11
Shares (Diluted)
70.8M
+1.2%
70.0M
-3.1%
72.3M
+5.0%
68.8M
+0.4%
68.5M
Bioventus (BVS) โ€” Financials